From: Cognitive function in recovered COVID-19 Lebanese patients with schizophrenia
 | Beta | Effect size (n2) | p-value | Confidence interval | |
---|---|---|---|---|---|
Lower | Upper | ||||
COVID-19 infection (Yes vs No) | −3.783 | 0.006 | 0.540 | −16.043 | 8.478 |
Gender (Female vs Male) | 0.110 | 0.002 | 0.737 | −0.541 | 0.760 |
Education level (University vs complementary) | 0.402 | 0.022 | 0.235 | −0.268 | 1.072 |
Education level (Secondary vs complementary) | 0.521 | 0.063 | 0.043 | 0.017 | 1.025 |
Positive PANSS | −0.018 | 0.004 | 0.601 | −0.086 | 0.050 |
Negative PANSS | −0.011 | 0.002 | 0.720 | −0.072 | 0.050 |
General psychopathology PANSS | −0.003 | 0.000 | 0.859 | −0.031 | 0.026 |
Depression (Calgary scale) | 0.021 | 0.001 | 0.775 | −0.125 | 0.167 |
BACS composite score at baseline | 0.027 | 0.000 | 0.920 | −0.511 | 0.566 |
duration between BACS assessment | −0.121 | 0.007 | 0.516 | −0.492 | 0.249 |
chlorpromazine equivalent dose | −0.003 | 0.018 | 0.278 | −0.001 | 0.000 |
ADS score | −0.082 | 0.031 | 0.159 | −0.196 | 0.033 |
Age | −0.044 | 0.033 | 0.147 | −0.103 | 0.016 |
Autonomy (total ADL) | −0.004 | 0.000 | 0.991 | −0.840 | 0.831 |
Interaction being diagnosed with COVID-19 and cognition at baseline | 0.816 | 0.116 | 0.005 | 0.255 | 1.377 |